At the recent annual meeting of the American Society of Hematology, researchers presented updated real-world data from the REALBiTE multicenter consortium. This consortium examined the outcomes of treatment with bispecific agents in patients with relapsed or refractory large B-cell lymphoma. The study focused on treatment sequencing strategies and predictors of response to therapy. Bispecific agents were evaluated in real-world clinical practice. The results provide insight into the efficacy of these agents after failure of standard therapy. Specific statistics on responses and survival were not reported in the content provided[1].